Enter Your keyword

Search the whole station Pandemic Supply

Huachenyang Won Section 337 Investigation,the Intellectual-property Lawsuit in US

HCY News Industry News 47520

On October 28, The US International Trade Commission (USITC) ruled that Huachenyang (Shenzhen) Technology Co., Ltd did not infringe the certain flocked swab patent rights of Copan Italia S.p.A of Brescia and Copan Industries, Inc.,.

This victory is symbolic that Huachenyang are now eyeing on oversea markets and patenting abroad through strengthening their capabilities in independent innovation in order to improve their core competitiveness in the international market.

In compliance with the unfair practices of the U.S. Tariff Act of 1930 against imports, U.S. corporations have launched an investigation under Section 337 and imposed sanctions on foreign enterprises.

In all 337 investigations, a total of 558 Chinese enterprises were defendants, and 29 Chinese enterprises were judged to be non-infringing, with a probability of roughly 5.2%.

Copan asked the USITC to start the Section 337 investigation on Huachenyang and other 7 Chinese interprises for patent infringement on July 9, 2021. Huachenyang together with 4 other Chinese interprises decided to response to the lawsuit.

The business hired a team of attorneys to actively respond to the lawsuit, cope with the applicant’s continual questionnaires, coordinate and arrange technical team to investigate the technical issues related to infringement. Collected a substantial amount of evidence regarding product development, production, and sales, to demonstrate that the product does not infringe the patent and it has sensible differences.

The victory in this response was not easy to come by, and the entire litigation lawyer fee was exorbitant. As well as a lot of effort and time were spent.

Huachenyang CEO, Mr. Gong said a enterprise must confront the challenges of globalization and uphold intellectual property rights if it wants to grow. Getting victorious in this section 337 investigation is crucial for Huachengyang, but it also shows how strong the industry are in R&D and international commerce.The establishment of the enterprise alliance, a robust framework for managing intellectual property, strong capabilities in technology research and development, and the direction of government policy were all factors in this success.

“HCY, Health care for you” is our forever mission. We dedicate to offering safe & reliable products and medical services with our global creditable partners. HCY has already supplied to WHO, MAYO clinic, MGI, DDC, Yale University, Qorvo, Quanterix, Thomas Scientific, SD biosensor, Cardinal Health, Cleveland Clinic, Mars Petcare & LumiraDx, etc. in the past years.

The prev: The next:

Related recommendations

    Expand more!